A New Era in Regenerative Aesthetics
In the dynamic field of regenerative and aesthetic medicine, few innovations have generated as much interest as exosomes. These nanoscale extracellular vesicles (EVs), secreted by cells to facilitate intercellular communication, offer unprecedented therapeutic potential thanks to their ability to modulate inflammation, stimulate tissue repair, and support skin and hair regeneration.
Yet, not all exosomes are created equal.
Through its patented Bio-Pulsed technology, AM Biotech has transformed the production and delivery of exosome-based treatments, enhancing their biological activity, clinical reliability, and regulatory readiness. In this article, we delve into the science behind exosomes, how Bio-Pulsing optimises their performance, and what the latest research reveals about their use in aesthetic and regenerative practice.
What Are Exosomes?
Exosomes are extracellular vesicles ranging in size from 30 to 150 nanometres, secreted by numerous cell types, including mesenchymal stem cells (MSCs). They carry a potent biological cargo of proteins, mRNAs, microRNAs (miRNAs), and lipids, components that are capable of influencing the behaviour of the recipient cell. Their naturally low immunogenicity and ability to cross physiological barriers have made them ideal vectors for regenerative medicine, from wound healing and scar repair to anti-aging and hair restoration therapies [1–3].
In dermatology and aesthetics, exosomes are being investigated for their ability to:
- Promote dermal fibroblast proliferation
- Boost collagen and elastin production
- Regulate pigmentation and inflammation
- Stimulate hair follicle activity
Despite this promise, conventional exosome therapies face limitations in yield, purity, and batch-to-batch consistency, issues that Bio-Pulsed technology seeks to solve.
The Challenge: Limitations of Conventional Exosome Production
Traditional methods of isolating exosomes from mammalian cells typically yield small quantities with inconsistent molecular content. Purification processes often leave behind residual proteins, cell debris, or microvesicles, which can compromise safety and efficacy. Additionally, most commercial exosomes are unstable at room temperature and require cold-chain storage, which increases the cost and logistical complexity for clinical use [3].
Bio-Pulsing: A Scientific Leap Forward
Bio-Pulsing is AM Biotech’s patented preconditioning process designed to radically enhance exosome production, purity, and bioactivity. This is achieved by stimulating non-human stem cells, specifically, pathogen-free chicken embryo-derived MSCs, with botanical cues such as Polygonum multiflorum extract.
This biochemical stimulation induces a surge in exosome secretion, up to 93 times higher than baseline, and enriches their cargo with regenerative proteins and miRNAs [4]. Preclinical findings confirm this: Bio-Pulsed cells upregulate RAB27A (a key exosome-release gene), leading to superior EV output and quality.
Critically, these exosomes are then ultra-purified to greater than 99.99% purity and lyophilised into a stable powder, offering a shelf life of up to 3 years at room temperature. This eliminates the need for cold-chain storage while enhancing clinical versatility.
Clinical Results: What the Data Say
AM Biotech’s lead product, ExoGiov®, and its brand LA EXO has been extensively validated in both laboratory and clinical settings:
In Vitro Efficacy
- Fibroblast proliferation: +113% with ExoGiov® vs. +87% with minoxidil
- Collagen Type I production: ↑ up to 389%
- Collagen Type III production: ↑ up to 340%
- Elastin expression: ↑ up to 390%
- Hair follicle dermal papilla cell growth: ↑ 127%
- Cytokine suppression (TNF-α, IL-6): ↓ up to 50%
These metrics strongly support the use of Bio-Pulsed exosomes in facial rejuvenation, scar repair, and hair restoration applications.
Clinical Trial Highlights
A 2025 IRB-approved clinical study involving 60 human participants using topical Bio-Pulsed AMSC-sEV formulations (LA EXO® ampoule and essence) reported:
- Wrinkle depth: ↓ 7.3%
- Collagen density: ↑ 18.2%
- Hair A/T ratio (anagen/telogen): ↑ 48.7%
- Hair shedding: ↓ 46.5%
- No adverse events or sensitivity reported [5]
These outcomes were achieved using standardized trichoscopy, ultrasound, and molecular assays such as qPCR and miRNA profiling, reinforcing the translational potential of this cell-free therapy.
Regulatory Compliance and Practical Benefits
AM Biotech’s use of non-human, avian-derived MSCs enables Bio-Pulsed exosomes to comply with regulations that restrict the use of human-derived materials in cosmetics (e.g., EU 1223/2009). In addition:
- INCI listing: ExoGiov® has secured International Nomenclature Cosmetic Ingredient registration.
- GMP-aligned: Manufacturing follows Good Manufacturing Practices.
- Shelf-stable: Lyophilised form avoids the need for refrigeration.
- Patent protected: Ensuring innovation exclusivity.
These features make Bio-Pulsed exosomes not only scientifically robust but also clinically practical and commercially viable.
Final Thoughts
For clinicians seeking cutting-edge, non-cellular regenerative therapies, Bio-Pulsed exosomes provide an elegant solution supported by both scientific evidence and clinical data. Whether used post-laser, in conjunction with microneedling, or as part of a bespoke facial or hair treatment protocol, these biologically active vesicles are setting a new standard in results-driven aesthetics.
With a robust safety profile, regulatory clearance, and strong clinical support, Bio-Pulsed exosomes represent a pivotal advance in regenerative medicine, offering a needle-free approach that eliminates the need for stem cells and systemic risks.
LA EXO exosomes are exclusively distributed in the UK and Ireland by Cosmeditech. For more information visit www.laexo.co.uk and www.cosmeditech.com
References
- Aheget H, Tristán-Manzano M, Mazini L, et al (2020) Exosome: A New Player in Translational Nanomedicine. J Clin Med 9:2380. https://doi.org/10.3390/jcm9082380
- Perocheau D, Touramanidou L, Gurung S, et al (2021) Clinical applications for exosomes: Are we there yet? Br J Pharmacol 178:2375–2392. https://doi.org/10.1111/bph.15432
- Ren X, Xu R, Xu C, Su J (2024) Harnessing exosomes for targeted therapy: strategy and application. Biomater Transl 5:46–58. https://doi.org/10.12336/biomatertransl.2024.01.005
- Shieh J-S, Chin Y-T, Chiu H-C, et al (2022) Bio-Pulsed Stimulation Effectively Improves the Production of Avian Mesenchymal Stem Cell-Derived Extracellular Vesicles That Enhance the Bioactivity of Skin Fibroblasts and Hair Follicle Cells. International Journal of Molecular Sciences 23:15010. https://doi.org/10.3390/ijms232315010
- Shieh J-S, Chin Y-T, Yeh T-T, et al (2025) Topical Application of Bio-Pulsed Avian MSC-Derived Extracellular Vesicles Enhances Hair Regrowth and Skin Rejuvenation: Evidence from Clinical Evaluation and miRNA Profiling. Current Issues in Molecular Biology 47:539. https://doi.org/10.3390/cimb47070539